FDB (First Databank) vs InpharmD (2026)
Embedded content against a mediated service. FDB supplies the drug knowledge sitting under most American prescribing systems, so its interaction and dose logic is the baseline every clinician already sees, delivered instantly and invisibly inside the workflow. InpharmD answers the question a clinician actually asked, with a board certified drug information pharmacist formulating the researchable question and reviewing what the model produces, which is the clearest load bearing human in the loop in this index. They serve different moments. For an interaction check at the point of prescribing, the embedded content wins because it is already there. For a formulary or pharmacy and therapeutics question the compendium does not cover, InpharmD is doing work FDB does not attempt.
- The drug knowledge sits underneath most prescribing systems in the United States, so its content is the baseline every additional layer is measured against.
- The licensing architecture is clean by design, embedding content in customers' own systems and placing hosting and processing questions with them.
- Its newer products are framed conservatively, with a prescription agent producing orders explicitly for physician review.
- A board certified drug information pharmacist sits between the model and the clinician on every response, which is the clearest human in the loop architecture in this index.
- The pipeline is published step by step, from inquiry parsing through pharmacist formulation to semantic retrieval, so a buyer can see where the model works and where the person does.
- A free pilot is offered explicitly with the pharmacy and therapeutics committee as the entry point, deployed at more than thirty health systems.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. FDB (First Databank) and InpharmD are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | FDB (First Databank) | InpharmD |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Clinical Reference & Evidence |
| Headquarters | South San Francisco, California, United States | Atlanta, Georgia |
| Website | fdbhealth.com | inpharmd.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards FDB (First Databank) its top capability grade on EHR and Interoperability Depth. Set against InpharmD, FDB (First Databank) grades higher on EHR and Interoperability Depth and Setting and Specialty Coverage. Its thinnest published disclosure sits on several axes, including AI Centrality, Model Supply Chain Disclosure and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards InpharmD its top capability grade on Autonomy and Oversight Model. Set against FDB (First Databank), InpharmD grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose FDB (First Databank) or InpharmD?
On the axes where the AI Health Index separates them, FDB (First Databank) grades higher on EHR and Interoperability Depth and Setting and Specialty Coverage, and InpharmD grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. InpharmD leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do FDB (First Databank) and InpharmD differ most?
The widest separation the AI Health Index records between FDB (First Databank) and InpharmD is on EHR and Interoperability Depth, where FDB (First Databank) grades A and InpharmD grades C. That axis sits in the Integration and Deployment group, so it should carry the most weight for a buyer whose binding constraint is how the product lands in the stack already in place.
Where do FDB (First Databank) and InpharmD grade the same?
The AI Health Index grades FDB (First Databank) and InpharmD the same on several axes, including Clinical and Operational Evidence, AI Safety and PHI Stewardship and FDA and Regulatory Status. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have FDB (First Databank) and InpharmD not disclosed?
At the last review, at least one of FDB (First Databank) and InpharmD published thin or absent detail on several axes, including AI Centrality, Model Supply Chain Disclosure and HIPAA and BAA Posture. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These answer on different clocks and that is the practical constraint: embedded drug content answers instantly inside the prescribing workflow, and a pharmacist mediated service answers well but not immediately, so ask InpharmD for its turnaround time distribution rather than an average.
InpharmD states plainly that it is not a covered entity or business associate platform and instructs users not to submit protected health information, which is unusually clear and also a real limit on how a question can be phrased. Neither publishes a security attestation or pricing.